drugset / Trial / NCT06178926
Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
RandomizedParallel-groupDouble-blindTreatment
Summary
Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
Timeline
- Start
- 2023-08-01
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cipepofol | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | Cipepofol | Small molecule | 0.3 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 1 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 2 mg/kg | Intravenous |